Colorectal cancer
Conditions
Interventions
Tegileridine Fumarate group (T group):Tiglitazidine for postoperative analgesia
Sufentanil group (S group):Sufentanil for postoperative analgesia
Sponsors
The First Affiliated Hospital of University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–64 years; 2. Scheduled for elective laparoscopic radical surgery for colorectal cancer; 3. American Society of Anesthesiologists (ASA) physical status I–III; 4. Normal preoperative cognitive function (MoCA score >=26), no history of anxiety or depression, no long-term use of sedative-hypnotics or opioids.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of allergies to related drugs or contraindications; 2. Patients with severe neurological diseases (such as epilepsy, post-stroke sequelae), psychiatric disorders (such as schizophrenia), or cognitive impairments before surgery; 3. Patients with severe cardiopulmonary or liver and kidney dysfunction; 4. Patients who have undergone radiotherapy, chemotherapy, or immunotherapy before surgery, as well as those with other malignant tumors; 5. Patients unable to cooperate with scale assessments after surgery; 6. Patients requiring transfer to the intensive care unit (ICU) for further treatment after surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QoR-15 score; | — |
Secondary
| Measure | Time frame |
|---|---|
| MoCA score;Time of first postoperative gas passage, defecation, and eating;Adverse reactions within 72 hours after surgery;time to first rescue analgesia; patient satisfaction ;VAS pain score at rest and during movement; | — |
Countries
China
Contacts
Public ContactSheng Wang
The First Affiliated Hospital of University of Science and Technology of China
Outcome results
None listed